Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Scientists discover that the CD74 protein could predict the effectiveness of immunotherapy, advancing colon cancer treatment.

NBC 5 Responds is taking a deep dive into health insurance denials and the creative solutions many are using to get their ...

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...

There is no single treatment for colon cancer, and options may include immunotherapy, surgery, chemotherapy, and radiation therapy. The aim of treatment will be to remove the cancer, prevent its ...

Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...

A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed ...

A new treatment for colorectal cancer that has spread to the liver is showing promising results in Dutch medical trials. The ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.